$CTMX
CytomX Therapeutics, Inc. Stock $ctmx

$ctmx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000095017022023190 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$946.0K	$16.92M	$17.59M
YoY Change	-95.2%	-3.82%	-1.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.07M	$10.49M	$11.09M
YoY Change	6.46%	-5.37%	28.45%
% of Gross Profit
Research & Development	$19.56M	$30.37M	$29.14M
YoY Change	-46.52%	4.2%	21.18%
% of Gross Profit
Depreciation & Amortization	$608.0K	$623.0K	$680.0K
YoY Change	-9.93%	-8.38%	13.33%
% of Gross Profit
Operating Expenses	$29.63M	$40.86M	$40.23M
YoY Change	-35.63%	1.56%	23.09%
Operating Profit		-$23.94M	-$22.64M
YoY Change		5.75%	52.0%
Interest Expense	$732.0K	$616.0K	$70.00K
YoY Change	902.74%	780.0%	-65.0%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$30.00K	-$13.00K
YoY Change	-85.71%	-330.77%	-13.33%
Pretax Income	-$27.95M	-$23.30M	-$22.58M
YoY Change	6.57%	3.15%	53.53%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$27.95M	-$23.30M	-$22.58M
YoY Change	6.57%	3.15%	53.53%
Net Earnings / Revenue	-2954.76%	-137.72%	-128.41%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.42	-$353.4K	-$346.3K
COMMON SHARES
Basic Shares Outstanding	66.08M	65.95M	65.16M
Diluted Shares Outstanding		65.91M	65.21M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$193.7M	$194.3M	$236.3M
YoY Change	-36.56%	-17.77%	-26.41%
Cash & Equivalents	$193.7M	$95.04M	$236.3M
Short-Term Investments	$0.00	$99.25M	$5.000K
Other Short-Term Assets	$7.466M	$4.278M	$3.822M
YoY Change	74.24%	11.93%	-31.75%
Inventory
Prepaid Expenses
Receivables	$35.99M	$1.712M	$887.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$237.1M	$200.3M	$241.0M
YoY Change	-23.59%	-16.9%	-29.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.072M	$5.710M	$6.271M
YoY Change	-14.9%	-8.95%	-79.37%
Goodwill	$949.0K	$949.0K	$949.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments			$99.97M
YoY Change
Other Assets	$27.00K	$895.0K	$902.0K
YoY Change	-97.0%	-0.78%	-60.78%
Total Long-Term Assets	$23.79M	$26.21M	$130.2M
YoY Change	-18.28%	-79.87%	273.17%
TOTAL ASSETS
Total Short-Term Assets	$237.1M	$200.3M	$241.0M
Total Long-Term Assets	$23.79M	$26.21M	$130.2M
Total Assets	$260.9M	$226.5M	$371.2M
YoY Change	-23.13%	-38.99%	-1.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.809M	$5.176M	$1.516M
YoY Change	-0.32%	241.42%	-57.89%
Accrued Expenses	$28.53M	$31.34M	$25.17M
YoY Change	-16.66%	24.53%	5.1%
Deferred Revenue	$121.3M	$61.33M	$73.09M
YoY Change	75.08%	-16.1%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$152.6M	$97.84M	$99.77M
YoY Change	43.54%	-1.94%	-2.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$194.0M	$100.2M	$159.8M
YoY Change	35.01%	-37.31%	-29.02%
Total Long-Term Liabilities	$194.0M	$100.2M	$159.8M
YoY Change	35.01%	-37.31%	-29.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$152.6M	$97.84M	$99.77M
Total Long-Term Liabilities	$194.0M	$100.2M	$159.8M
Total Liabilities	$346.6M	$198.0M	$259.6M
YoY Change	38.64%	-23.71%	-20.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$722.9M	-$605.1M	-$507.5M
YoY Change	35.44%	19.23%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$85.75M	$28.47M	$111.7M
YoY Change
Total Liabilities & Shareholders Equity	$260.9M	$226.5M	$371.2M
YoY Change	-23.13%	-38.99%	-1.06%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$27.95M	-$23.30M	-$22.58M
YoY Change	6.57%	3.15%	53.53%
Depreciation, Depletion And Amortization	$608.0K	$623.0K	$680.0K
YoY Change	-9.93%	-8.38%	13.33%
Cash From Operating Activities	-$1.394M	-$33.84M	-$29.70M
YoY Change	-95.53%	13.95%	20.24%
INVESTING ACTIVITIES
Capital Expenditures	$182.0K	-$410.0K	-$268.0K
YoY Change	-174.29%	52.99%	-66.5%
Acquisitions
YoY Change
Other Investing Activities	$100.0M	$0.00	$10.00M
YoY Change		-100.0%	-111.2%
Cash From Investing Activities	$99.82M	-$410.0K	$9.734M
YoY Change	-40842.04%	-104.21%	-110.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	190.0K	0.000	104.0K
YoY Change	-72.18%	-100.0%	-48.0%
NET CHANGE
Cash From Operating Activities	-1.394M	-33.84M	-29.70M
Cash From Investing Activities	99.82M	-410.0K	9.734M
Cash From Financing Activities	190.0K	0.000	104.0K
Net Change In Cash	98.61M	-34.25M	-19.86M
YoY Change	-420.65%	72.46%	-82.67%
FREE CASH FLOW
Cash From Operating Activities	-$1.394M	-$33.84M	-$29.70M
Capital Expenditures	$182.0K	-$410.0K	-$268.0K
Free Cash Flow	-$1.576M	-$33.43M	-$29.43M
YoY Change	-94.91%	13.6%	23.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
	dei	Entity Central Index Key EntityCentralIndexKey	0001501989
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#LicenseAndServiceMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37587
	dei	Entity Registrant Name EntityRegistrantName	CytomX Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3521219
	dei	Entity Address Address Line1 EntityAddressAddressLine1	151 Oyster Point Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1468000
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	61325000
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q3	us-gaap	Assets Assets	226492000
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	66084367
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95036000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	205530000
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	99254000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	99696000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1712000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	790000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4278000
CY2021Q4	us-gaap	Assets Assets	339411000
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5176000
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	515-3185
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2818000
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
	dei	Trading Symbol TradingSymbol	CTMX
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31340000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34236000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4285000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	200280000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	310301000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5710000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5960000
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	911000
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1021000
CY2022Q3	us-gaap	Goodwill Goodwill	949000
CY2021Q4	us-gaap	Goodwill Goodwill	949000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16830000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19362000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	895000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	901000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	69262000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	97841000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	106316000
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	85122000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	125660000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15055000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18056000
CY2022Q3	us-gaap	Liabilities Liabilities	198018000
CY2021Q4	us-gaap	Liabilities Liabilities	250032000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65950242
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65950242
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65392758
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65392758
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	634357000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	623344000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-795000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-242000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-605089000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72650000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-533724000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	28474000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	89379000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226492000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	339411000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16915000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17587000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52217000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49846000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30367000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29143000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	92085000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77615000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10490000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11085000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	32782000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29704000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	40857000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	40228000
	us-gaap	Operating Expenses OperatingExpenses	124867000
	us-gaap	Operating Expenses OperatingExpenses	107319000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23942000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22641000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57473000
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	616000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	70000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	946000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	182000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	339000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-90000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-23296000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-22584000
	us-gaap	Net Income Loss NetIncomeLoss	-71365000
	us-gaap	Net Income Loss NetIncomeLoss	-57381000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	367000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	37000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-553000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	99000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22929000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22547000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71918000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57282000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.35
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.35
CY2021Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.35
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.09
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.09
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.90
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.90
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65912334
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65912334
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65208066
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65208066
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65618162
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65618162
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63759585
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63759585
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	89379000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3370000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-677000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23885000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	68194000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	91000
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	360000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4490000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-243000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24184000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48708000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2695000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	367000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-23296000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	28474000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	49803000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107712000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1023000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3034000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-15554000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	146022000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	173000
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	518000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3425000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	58000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-19243000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	130953000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	104000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3164000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	37000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-22584000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	111674000
	us-gaap	Profit Loss ProfitLoss	-71365000
	us-gaap	Profit Loss ProfitLoss	-57381000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	110000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	110000
	ctmx	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	1725000
	ctmx	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	1921000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	47000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-287000
	us-gaap	Share Based Compensation ShareBasedCompensation	10555000
	us-gaap	Share Based Compensation ShareBasedCompensation	9623000
	ctmx	Noncash Lease Expense NoncashLeaseExpense	-2532000
	ctmx	Noncash Lease Expense NoncashLeaseExpense	-2325000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	986000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	89000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3274000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1270000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2441000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1358000
	ctmx	Increase Decrease In Accrued And Other Liabilities Noncurrent IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent	-5897000
	ctmx	Increase Decrease In Accrued And Other Liabilities Noncurrent IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent	-550000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-48475000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-47271000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-109394000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87839000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1558000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1364000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	99898000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	123996000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1558000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22734000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107712000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	458000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1818000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	458000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109530000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-110494000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	44425000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206447000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	192776000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95953000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	237201000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	205530000
CY2022Q3	ctmx	Accrued Research And Clinical Current AccruedResearchAndClinicalCurrent	15252000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Description of the Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95036000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	236284000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	191859000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	917000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95953000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206447000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	237201000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	192776000
CY2022Q3	ctmx	Cash Cash Equivalents And Investments Amortized Cost Basis CashCashEquivalentsAndInvestmentsAmortizedCostBasis	177230000
CY2022Q3	ctmx	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax	795000
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	176435000
CY2021Q4	ctmx	Cash Cash Equivalents And Investments Amortized Cost Basis CashCashEquivalentsAndInvestmentsAmortizedCostBasis	266591000
CY2021Q4	ctmx	Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax	242000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	266349000
CY2021Q4	ctmx	Accrued Research And Clinical Current AccruedResearchAndClinicalCurrent	18861000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6325000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9576000
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1742000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14261417
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.71
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3961000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3618000
CY2022Q3	us-gaap	Restructuring Reserve RestructuringReserve	3876000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	184000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	713000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31340000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34236000
CY2022Q3	us-gaap	Revenues Revenues	16915000
CY2021Q3	us-gaap	Revenues Revenues	17587000
	us-gaap	Revenues Revenues	52217000
	us-gaap	Revenues Revenues	49846000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	194922000
	ctmx	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	0
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-48475000
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	146447000
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	146400000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12192216
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4962418
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100990
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.98
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2792227
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.95
CY2022Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.40
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	200000
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	7146000
CY2022Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	3119000
CY2022Q3	us-gaap	Restructuring Reserve Translation And Other Adjustment RestructuringReserveTranslationAndOtherAdjustment	-151000
CY2022Q3	us-gaap	Restructuring Reserve RestructuringReserve	3876000
CY2022Q3	us-gaap	Restructuring Costs RestructuringCosts	7900000

Files In Submission

Name	View Source	Status
0000950170-22-023190-index-headers.html	Edgar Link	pending
0000950170-22-023190-index.html	Edgar Link	pending
0000950170-22-023190.txt	Edgar Link	pending
0000950170-22-023190-xbrl.zip	Edgar Link	pending
ctmx-20220930.htm	Edgar Link	pending
ctmx-20220930.xsd	Edgar Link	pending
ctmx-ex10_1.htm	Edgar Link	pending
ctmx-ex10_2.htm	Edgar Link	pending
ctmx-ex10_3.htm	Edgar Link	pending
ctmx-ex10_4.htm	Edgar Link	pending
ctmx-ex10_5.htm	Edgar Link	pending
ctmx-ex10_6.htm	Edgar Link	pending
ctmx-ex31_1.htm	Edgar Link	pending
ctmx-ex31_2.htm	Edgar Link	pending
ctmx-ex32_1.htm	Edgar Link	pending
ctmx-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
ctmx-20220930_lab.xml	Edgar Link	unprocessable
ctmx-20220930_pre.xml	Edgar Link	unprocessable
ctmx-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctmx-20220930_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctmx-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTMX
CytomX Therapeutics, Inc. Stock $ctmx

2022 Q4 Form 10-Q Financial Statement

#000095017022023190 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTMX CytomX Therapeutics, Inc. Stock $ctmx

2022 Q4 Form 10-Q Financial Statement

#000095017022023190 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTMX
CytomX Therapeutics, Inc. Stock $ctmx